Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
Tifcemalimab plus toripalimab showed promising antitumor activities with acceptable safety, especially in advanced refractory SCLC.
Authors
- Bang.an Peng
- Runxiang Yang (ORCID: https://orcid.org/0000-0002-9974-248X)
- Ying Cheng (ORCID: https://orcid.org/0000-0001-9908-597X)
- Dongqing Lv (ORCID: https://orcid.org/0000-0002-1132-0910)
- Bing Xia (ORCID: https://orcid.org/0000-0002-9178-5493)
- Mingjun Shen
- Xi-Cheng Wang (ORCID: https://orcid.org/0000-0002-8490-9785)
- Qiming Wang (ORCID: https://orcid.org/0000-0003-3217-1077)
- Chong Li (ORCID: https://orcid.org/0000-0002-9215-6779)
- Jie Wang (ORCID: https://orcid.org/0000-0002-5602-0487)
- Jing Xu
- Xiaoqing Liu
- Yan Yu (ORCID: https://orcid.org/0000-0001-5598-763X)
- Man Su
- Tienan Yi (ORCID: https://orcid.org/0009-0008-8678-4841)
- Wei Zhang (ORCID: https://orcid.org/0009-0004-6570-4153)
- Liang Han (ORCID: https://orcid.org/0000-0002-5226-5508)
Institutions
- Nanchang University (CN)
- Harbin Medical University (CN)
- Nantong University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Kunming Medical University (CN)
- Wenzhou Medical University (CN)
- Peking Union Medical College Hospital (CN)
- Chinese PLA General Hospital (CN)
- Bioscience (China) (CN)
- Bioscience Research (US)
- 307th Hospital of Chinese People’s Liberation Army (CN)
- Jilin Province Tumor Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- The First People's Hospital of Changzhou (CN)
- PLA 306 Hospital (CN)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
- Xiangyang Central Hospital (CN)
- The Affiliated Taizhou People's Hospital of Nanjing Medical University (CN)
- Taizhou Central Hospital (CN)
- Xuzhou Central Hospital (CN)
- Henan Cancer Hospital (CN)
- Zhejiang Taizhou Hospital (CN)
- First Affiliated Hospital of Nanchang University (CN)
- Hangzhou Cancer Hospital (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-05-16
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-0022
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14